Blood samples were collected up to @-h postdose on day @ ( gemigliptin ) and day @ ( gemigliptin and glimepiride ) following treatment A , and on day @ ( glimepiride ) following treatment B. Concentrations of gemigliptin , glimepiride , and metabolites were determined using validated liquid chromatography-tandem mass spectrometry ( LC-MS/MS ) .